Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lemuteporfin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LTS/Vehicle | EXPERIMENTAL | Within subject control study |
| Name | Type | Description |
|---|---|---|
| Lemuteporfin | DRUG | lemuteporfin topical solution, 1% |
Inclusion Criteria: * Stage 1 only: healthy subjects * Stage 1-4: male or female subjects age 18 years or older * Stage 2: subjects with sebum excretion rate of 4 or higher on forehead * Stage 2-4: subjects with at least 2 inflammatory acne lesions on the forehead * Stage 3-4: subjects with sebum e...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | 1% Clascoterone |
| Sanofi SA Sponsored ADR | SNY | 3 | PHASE1 | Acne mRNA vaccine |
| Hoth Therapeutics, Inc. | HOTH | 1 | PHASE2 | HT-001 2%, HT-001 1%, HT-001 0.5% |
| Sagimet Biosciences Inc. Class A | SGMT | 1 | PHASE1 | TVB-3567 |
| Bausch Health Companies Inc. | BHC | 1 | - | clindamycin, adapalene and benzoyl peroxide |
Lemuteporfin is an investigational small molecule being developed for the treatment of acne. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and remains under study to evaluate its safety and potential efficacy in patients with mild acne.
Lemuteporfin is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research to evaluate the drug's safety and tolerability in subjects with mild acne.
Lemuteporfin is in Phase 1 clinical development. A Phase 1/2 sequentially staged safety study has been completed, involving 129 participants, including healthy subjects and those with mild acne. The drug remains investigational and has not received regulatory approval for any use.
Lemuteporfin has one completed clinical trial registered as NCT01490736, titled 'Phase 1/2 Sequentially Staged Safety Study in Healthy Subjects and Subjects With Mild Acne.' This study enrolled 129 participants in Canada, included healthy volunteers, and was double-blind but uncontrolled.
No alternative names for Lemuteporfin have been disclosed in the available clinical trial information. The drug is identified solely by its investigational name, Lemuteporfin, in the context of its development for acne.